BioVie announces three presentations from studies of NE3107

BioVie announced details of three presentations given from studies of NE3107 in the treatment of Parkinson’s Disease, or PD, at the 2023 International Congress of Parkinson’s Disease and Movement Disorders, being held in Copenhagen, Denmark August 27-31. The three presentations are as follows: Effects of NE3107 Anti-Inflammatory Treatment on Motor Activity and Neurodegenerative Features of Parkinson’s Disease in a Marmoset Monkey Model; Safety and Pharmacokinetics of Anti-Inflammatory NE3107 Treatment in Carbidopa/Levodopa-Treated; A Randomized, Phase 2a, Double-Blind, Placebo-Controlled Clinical Trial with NE3107 Adjunctive to Carbidopa/Levodopa in Patients with Parkinson’s Disease.